Update on community-acquired pneumonia. New pathogens and new concepts in treatment
Mandell, L.A.
Postgraduate Medicine 118(4): 35-6 41-6
2005
ISSN/ISBN: 0032-5481 PMID: 16296262 Document Number: 594669
Recent years have witnessed the emergence of new pathogens linked to community-acquired pneumonia (CAP) along with new antibiotics designed to combat them. In this article, Dr Mandell presents an expert's view on these developments in the context of treatment guidelines for CAP. He also explores monotherapy versus combination therapy, the efficacy of rapid initiation of treatment, and short-course therapy as a hedge against antimicrobial resistance.
Document emailed within 1 workday
Related Documents
Zubairi, A.B.S.; Zafar, A.; Salahuddin, N.; Haque, A.S.; Waheed, S.; Khan, J.A. 2012: Atypical pathogens causing community-acquired pneumonia in adults JPMA. Journal of the Pakistan Medical Association 62(7): 653-656Braun, J.J.; de Graaff, C.S.; de Goey, J.; Zwinderman, A.H.; Petit, P.L. 2004: Community-acquired pneumonia: pathogens and course in patients admitted to a general hospital Nederlands Tijdschrift Voor Geneeskunde 148(17): 836-840
Prapphal, N.; Suwanjutha, S.; Durongkaveroj, P.; Lochindarat, S.; Kunakorn, M.; Deerojanawong, J.; Chantarojanasiri, T.; Supanitayaonon, Y.; Janedittakarn, P. 2006: Prevalence and clinical presentations of atypical pathogens infection in community acquired pneumonia in Thailand Journal of the Medical Association of Thailand 89(9): 1412-1419
Luna, C.M.; Efron, E.D.; Schiavi, E.; Gené, R.J.; Famiglietti, A.; Jolly, E.C.; Niederman, M.S. 1997: Community-acquired pneumonia in adults. Clinical practice guideline for Argentina. Study Group on Community Acquired Pneumonia Medicina 57(3): 343-355
Mamum, M. 1998: Community acquired pneumonia in elderly people. this pneumonia is only a small fraction of all hospital cases of chest infection and pneumonia Bmj 317(7171): 1524-1525
Youngchaiyud, P.; Permpikul, C.; Thamlikitkul, V.; Charoenratanakul, S.; Nana, A. 1991: Treatment of community-acquired pneumonia with ofloxacin Journal of the Medical Association of Thailand 74(2): 61-65
Valverde Garrido, R.; Vegas Serrano, A.; Crespo Rico, S.; Vereda Ortiz, A.; Díez Sebastián, J. 2002: Study of the diversity in treatment of community-acquired pneumonia Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 15(4): 346-351
Wasielewski, S. 2005: Initial treatment can lighten low-severity community-acquired pneumonia Medizinische Monatsschrift für Pharmazeuten 28(11): 413
Parola, D.; Dell'Orso, D.; Terzano, C. 2000: Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia Recenti Progressi in Medicina 91(1): 12-15
Vizel', A.A.; Lysenko, G.V. 2013: Comparative analysis of the treatment of inpatients with community-acquired pneumonia and its different outcomes Klinicheskaia Meditsina 91(3): 41-44
Aleva, R.M.; Boersma, W.G. 2005: Guideline 'Diagnosis and treatment of community-acquired pneumonia' from the Dutch Thoracic Society Nederlands tijdschrift voor geneeskunde 149(45): 2501-2507
Granton, J.T.; Grossman, R.F. 1993: Community-acquired pneumonia in the elderly patient. Clinical features, epidemiology, and treatment Clinics in Chest Medicine 14(3): 537-553
Elston, D.M. 2007: Status update: hospital-acquired and community-acquired methicillin-resistant Staphylococcus aureus Cutis 79(6 Suppl): 37-42
Lin, C-Chung.; Lee, C-Hung.; Chen, C-Zuei.; Chu, Y-Chin.; Hung, T-Jen.; Chang, H-Yu.; Hsiue, T-Ren. 2005: Value of the pneumonia severity index in assessment of community-acquired pneumonia Journal of the Formosan Medical Association 104(3): 164-167
Iutanova, N.S. 2004: Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia Antibiotiki i Khimioterapiia 49(3): 17-21
Sánchez, M.E.; Gómez, J.; Gómez Vargas, J.; Baños, V.; Ruiz Gómez, J.; Muñoz, L.; Simarro, E.; Soto, M.C.; Canteras, M.; Valdés, M. 1998: Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 11(2): 132-138
Fine, M.J.; Medsger, A.R.; Stone, R.A.; Marrie, T.J.; Coley, C.M.; Singer, D.E.; Akkad, H.; Hough, L.J.; Lang, W.; Ricci, E.M.; Polenik, D.M.; Kapoor, W.N. 1997: The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study Archives of Internal Medicine 157(1): 47-56
Kiryszewska, A.; Antczak, A. 2011: Pathogens isolated from patients with community-acquired lower respiratory tract infections Medycyna Doswiadczalna i Mikrobiologia 63(4): 333-339
Wessels, F.; Anderson, A.N.; Ebrahim, O. 1998: Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. a pharmaco-economic study based on a meta-analysis South African Medical Journal 88(3): 251-255
Krykhtina, M.A.; Bielosludtseva, K.O.; Botvinikova, L.A.; Matikina, N.M. 2019: Lung vessels thrombosis in hospitalized patients with community-acquired pneumonia: role of endothelial function, hemostasis, fibrinolysis and inflammation on different phases of treatment Wiadomosci Lekarskie 72(8): 1463-1465